Clinical trials
Carcinoma, Non-Small-Cell Lung trials in the United States with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
86 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 8 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 10 |
| 2022 | 5 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 86 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Jun Zhang, MD, PhD | 2 |
| Massachusetts General Hospital | 2 |
| NGM Biopharmaceuticals, Inc | 2 |
| Raghu Nandan, M.D., Inc | 2 |
| Shanghai EpimAb Biotherapeutics Co., Ltd. | 2 |
| Tularik | 2 |
| University of Wisconsin, Madison | 2 |
| Accuray Incorporated | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 86 |
| Lung Neoplasms | 37 |
| Melanoma | 9 |
| Stomach Neoplasms | 9 |
| Small Cell Lung Carcinoma | 8 |
| Breast Neoplasms | 7 |
| Colorectal Neoplasms | 7 |
| Ovarian Neoplasms | 7 |
| Carcinoma, Renal Cell | 6 |
| Neoplasms | 6 |
Trials
Showing 1 to 25 of 86. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.